Seed Therapeutics Inc. signed a massive deal with Eli Lilly and Co. on Nov. 12, a date that resonated deeply with Seed’s CEO, Lan Huang. Twenty-one years earlier to the day she published a pioneering paper on cancer signaling pathways involving p53 degradation in Science. “It’s a magical coincidence that exactly 21 years later we have this deal with Lilly,” she told BioWorld, a deal with protein degradation at its core. In the new research collaboration and license agreement, Seed will receive $10 million cash up front to fund research along with a $10 million equity investment from Lilly.
3D Medicines Inc. has licensed in from Aravive Inc. a phase Ib-completed GAS6/AXL inhibitor known as AVB-500 in a deal worth up to $219 million. The Chinese firm will have the rights to develop and commercialize the drug candidate across all oncology indications in mainland China, Hong Kong, Macau and Taiwan.
HONG KONG – Kira Pharmaceuticals is riding high after completing a $46 million fundraiser and appointing Frederick Beddingfield as CEO. “The $46 million comprises a series A of $18 million and a series B of $26 million, with investors Quan Capital, 6 Dimensions Capital, Qiming Venture Partners, and Sinopharm Capital participating in both rounds,” Beddingfield told BioWorld.
RSS
